NEW YORK (GenomeWeb News) – Genalyte today said that it has inked an agreement with the Barbara Davis Center for Childhood Diabetes at the University of Colorado School of Medicine to collaborate on the further development of multiplexed antigen panels for the early detection of T1D.
The San Diego-based multiplex array technology firm also announced the launch of its Type 1 diabetes antigen panel, which runs on its Maverick Detection System. The firm said the panel is the "first multiplexed assay that measures seven autoantibodies associated with the destruction of pancreatic islet cells seen in type 1 diabetes."
Genalyte provided few details regarding the collaboration with the Davis Center, other than noting that it will involve research being carried out by George Eisenbarth and Liping Yu. Further terms were not disclosed.
"The unique capabilities of our Maverick detection platform have the potential to provide researchers and clinicians with tools to detect and track this process from an early stage, when interventions to interrupt the disease process may be feasible," Genalyte CSO Martin Gleeson said in a statement.
The T1D panel that was launched today measures autoantibodies to insulin, proinsulin, GAD 65, GAD 67, IA-2 (PTPRN, ICA512), phogrin (PTPRN2, IA-2ß) and ZnT8 (SLC30A8), and provides results in 15 minutes, said Genalyte.